Orexo Interim Report Q2 2019
Improving all fundamentals Q2 2019 highlights · Total net revenues of SEK 201.2 million (199.7), up 0.8 percent and 19.1 percent when excluding ex-US milestone payment of SEK 30.8 million in Q2 2018 · Zubsolv® US net revenues of SEK 184.4 million (158.4), up 16.4 percent in SEK and 6.7 percent in local currency · EBITDA of SEK 60.4 million (50.6), up 19.4 percent · US EBIT of SEK 87.5 million (55.5), up 57.6 percent · Cash flow from operating activities of SEK 46.1 million (39.0), building a cash balance of · SEK 697.0 million (494.8) · Net earnings of SEK 54.6